Viveve Medical Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	no data
Participación del CEO	n/a
Permanencia media de la dirección	6.3yrs
Promedio de permanencia en la Junta Directiva	6.8yrs

Actualizaciones recientes de la dirección

Recent updates

Viveve to get US patent for technology to treat female stress urinary incontinence

Oct 04

Viveve jumps 19% after FDA clearance for expansion of manufacturing treatment tips

Dec 03

CEO

Viveve Medical no tiene CEO, o no tenemos datos al respecto.

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Jim Robbins	Senior VP of Finance & Administration and Principal Accounting & Financial Officer	6.8yrs	US$701.05k	sin datos
Deborah Jorn	Senior Advisor to the CEO & Director	6yrs	US$208.88k	sin datos
Martin Kerber	Vice President of Research	6.3yrs	sin datos	sin datos
Jeannie Swindle	Senior Director of Corporate Communications	no data	sin datos	sin datos
Jeff Sinclair	Vice President of International Sales	no data	sin datos	sin datos
Gary Kaiser	Vice President of Global Marketing	no data	sin datos	sin datos
Lori McMillan	Vice President of Human Resources	7yrs	sin datos	sin datos
Suzon Lommel	Senior Vice President of Regulatory & Quality Affairs	6.3yrs	sin datos	sin datos

6.3yrs

Permanencia media

65yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de VIVE es experimentado (6.3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Deborah Jorn	Senior Advisor to the CEO & Director	8yrs	US$208.88k	sin datos
Arlene Morris	Independent Director	8yrs	US$232.63k	sin datos
Steven Basta	Independent Chairman of the Board	5.7yrs	US$469.44k	sin datos
Alan Wein	Member of Clinical Advisory Board in Urinary Incontinence	no data	sin datos	sin datos
Sharon Presnell	Independent Director	3.6yrs	US$196.13k	sin datos
Roger Dmochowski	Member of Clinical Advisory Board in Urinary Incontinence	no data	sin datos	sin datos
Mickey Karram	Member of Clinical Advisory Board in Urinary Incontinence	no data	sin datos	sin datos
Kathleen Kobashi	Member of Clinical Advisory Board in Urinary Incontinence	no data	sin datos	sin datos
Scott MacDiarmid	Member of Clinical Advisory Board in Urinary Incontinence	no data	sin datos	sin datos
Eric Rovner	Member of Clinical Advisory Board in Urinary Incontinence	no data	sin datos	sin datos

6.8yrs

Permanencia media

61yo

Promedio de edad

Junta con experiencia: La junta directiva de VIVE se considera experimentada (6.8 años de antigüedad promedio).

Viveve Medical Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Viveve Medical, Inc. Appoints Sharon Collins Presnell to the Board of Directors and Its Audit Committee, Effective October 28, 2020

Recent updates

InMode Ltd. (NasdaqGS:INMD) acquired Intellectual Property Assets of Viveve Medical Inc.

Viveve Medical, Inc.(OTCPK:VIVE) dropped from NASDAQ Composite Index

Viveve Medical, Inc. Intends to File A Form 15 with the Securities and Exchange Commission

Viveve Medical, Inc. Announces Completion of Pivotal US Pursuit Trial for Female Stress Urinary Incontinence

Viveve Medical Receives Notice from the Listing Qualifications Staff of Nasdaq

Viveve Medical Receives a Non-Compliance Letter from Nasdaq

Price target decreased to US$4.68

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Viveve Medical, Inc. announced that it has received $0.014675 million in funding

Viveve Medical, Inc. Announces Notice of Allowance for Second U.S. Method Patent for Treating Female Stress Urinary Incontinence

Viveve to get US patent for technology to treat female stress urinary incontinence

Viveve Medical, Inc. Launches Rebranding Initiative to Reflect Focus on Treatment of Female Stress Urinary Incontinence in Anticipation of U.S. Pivotal Pursuit Trial Readout

Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Viveve Medical, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Viveve Medical receives patent for dual-energy technology in Taiwan

Viveve Medical Receives a Letter from Nasdaq Regarding Minimum Bid Price Requirement

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Price target decreased to US$6.88

Consensus revenue estimates fall by 15%

Price target decreased to US$9.63

Viveve Medical, Inc. Announces Initiation of Pivotal U.S. Pursuit Trial in Stress Urinary Incontinence

Viveve Medical, Inc. has completed a Composite Units Offering in the amount of $23.999988 million.

Viveve under pressure after upsizes capital raise, prices offering at $3.40

Viveve Regains Compliance with Nasdaq Continued Listing Rules

Viveve regains compliance with Nasdaq

Viveve Announces FDA 510K Approval to Expand Manufacturing of Treatment Tips

Viveve jumps 19% after FDA clearance for expansion of manufacturing treatment tips

Viveve Medical, Inc. to Report Q3, 2020 Results on Nov 12, 2020

Viveve Medical, Inc. Appoints Sharon Collins Presnell to the Board of Directors and Its Audit Committee, Effective October 28, 2020

Viveve Medical, Inc. to Report Q2, 2020 Results on Aug 13, 2020

Viveve Medical, Inc. announced that it expects to receive $10 million in funding from Lincoln Park Capital, LLC

CEO

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad